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Introduction
Therapies that target the drivers of individual breast cancers have substantially improved the outcome of women with breast cancer, in particular endocrine therapies for luminal type cancers that express the oestrogen receptor, and trastuzumab for cancers with HER2 amplification (1) . However, for the approximately 10-15% of breast cancers that are triple negative (TN), cancers that express neither the oestrogen or progesterone receptors nor have amplification of HER2, the oncogenic drivers are poorly understood (2) (3) (4) (5) . This subgroup of cancers has a poor prognosis in the adjuvant setting (6, 7) , and is highly proliferative with a short time from relapse to death (8) . There is substantial overlap between TN breast cancers and the basal-like subtype of breast cancer, approximately 80% of TN breast cancers are basal-like (9), and therefore the two terms describe a broadly similar group of cancers. Identifying the oncogenic drivers of TN breast cancer and basal-like beast cancer is a priority if the outcome of women with this group of cancers is to be improved.
The oncogenic drivers, and the factors that promote TN tumour growth, are largely unclear with current evidence pointing to substantial heterogeneity (5, 10) . Mutations of PIK3CA are found in less than 10% TN breast cancers (11) , although the tumour suppressor PTEN may also be lost in a high proportion of these cancers (12) , and no other high frequency kinase gene mutations have been identified (13, 14) . Focal amplifications are found in the majority of TN cancers, although TN cancers often exhibit high levels of genomic instability (15, 16) and amplification of each individual genomic locus is only present in a small proportion of cancers (5) . Significant progress has been made in identifying commonly activated signal transduction pathways in TN and basal-like breast cancers. Deletion of the phosphatase PTPN12 may set up a permissive environment for oncogenic tyrosine kinase signalling in TN cancer (17) . TN cancer cell lines show high sensitivity to SRC inhibitors in vitro (18) , and MAPK pathway activation is more prominent in these cancers than luminal type cancers in vitro (4, 19) . In a subset of cancers EGFR has potentially been shown to be oncogenic in vitro (19) and there is recent clinical trial data supporting EGFR as a therapeutic target in a small proportion of TN cancers (20) . The oncogenic drivers that activate the MAPK pathway in the remaining cancers are unknown.
We have previously suggested that amplification of the fibroblast growth factor receptor genes may represent a therapeutic target in breast cancer, with amplification of FGFR1 occurring in approximately 10% of breast cancers (21) , predominantly of luminal subtype (22) . Amplification of FGFR2 also occurs more rarely being found in only ~1-2% of breast cancers overall, although approximately 4% of TN breast cancer have FGFR2 amplification (5) . These data suggest that aberrant activation of FGF signalling can play a role in breast tumourigenesis (23) . In this study we examine the prevalence of FGFR signalling as a driver in breast cancer, analysing the sensitivity of a panel of breast cancer cell lines to PD173074, a potent and selective FGFR inhibitor (24) . We find that TN, and basal-like, breast cancer cell lines frequently show sensitivity to FGFR inhibition, and analyse the potential mechanisms that may explain this sensitivity.
Materials and Methods

Cell lines, materials and antibodies
Cell lines were obtained from ATCC or Asterand, and maintained in phenol red free DMEM or RPMI with 10% FBS (PAA gold) and 2mM L-glutamine (Sigma-Aldrich, Dorset, UK). All cell lines were banked in multiple aliquots on receipt to reduce risk of phenotypic drift, and identity confirmed by STR profiling with the PowerPlex 1.2 System (Promega) and arrayCGH profiling. PD173074 and recombinant FGF2 were from Sigma. siRNA were from Dharmacon 
Allocation of molecular subtype and receptor status
Breast cancer cell lines were ascribed to be triple negative as described by Neve et al (25) , with the exception of MDAMB453 which is HER2 amplified (26) . CAL51, CAL120, MFM223 and SUM52PE are ER, PR and HER2 negative by western blotting as previously described (5), S68 is ER positive by western blotting, and VP229 and JIMT1 are HER2 amplified as assessed by HER2 FISH and array Comparative Genomic Hybridisation (data not shown).
Cell line gene expression subtype was as described by Neve et al, with the exception of CAL51 and CAL120 that are of Basal B subtype using the cancer class prediction of Neve et al (5) .
Breast cancers in a tissue microarray (27) were classified into the molecular subtypes using the immunohistochemical surrogate described by Nielsen et al (28) and Cheang et al (29) .
Triple negative cancers were divided into core basal-like (positive for EGFR or CK5/6) and non-basal TN (negative for EGFR and CK5/6).
Cell line drug sensitivity, siRNA transfection, and FGF2 neutralising antibody
Cell lines were transfected with siRNA (50nM final concentration) in 96 well plates with RNAiMax (Invitrogen) or Dharmafect4 (Dharmacon) according to manufacturers instructions, and survival was assessed with Cell Titre-Glo cell viability assay (Promega, Madison, WI) after 5 days growth. For sensitivity to PD173074 cells were plated in 96 well plates, and starting 24 hours post plating were exposed for 72 hours to 1μM PD173074 or vehicle, and survival assessed using Cell Titre-Glo. For assessment of activated caspase 3/7 cells were treated as for sensitivity to PD173074, assessed using the Apo-ONE® Homogeneous Caspase-3/7 Assay (Promega) according to manufacturer's instructions, and the level of 
Anchorage independent growth
Unless stated otherwise, assays of anchorage independence where in plates coated with 1.2% polyHEMA (poly(2-hydroxyethylmethacrylate, Sigma) in 95% ethanol, as previously described (30) . Soft agar assays were performed as previously described (22) .
Western blotting and FACS
Indicated cell lines where grown on 10cm plates, treated as indicated, and lysed in NP40 lysis buffer. Western blots were carried out with precast TA or Bis-Tris gels (Invitrogen) as previously described (22) . FACS analysis was performed as previously described (22) . 
Quantitative RT-PCR
cDNA was synthesised from RNA using Superscript III and random hexamers (Invitrogen).
Quantitative PCR was performed as previously described (22) . Expression of FGF2 
FGF2 immunohistochemistry
FGF2 imunohistochemistry was performed on a tissue microarray, extensive characterisation of which has been reported previously (27). Antigen retrieval was with pH 6.0 citrate buffer for 30 minutes at 90°C, before FGF2 antibody (rabbit polyclonal 500-P18 PeproTech, Rocky Hill, NJ) 1:100 dilution for 60 minutes and development with dual Envision kit (Dako®, Glostrup, Denmark). FGF2 was scored by two observers (JSRF and NCT) blinded to the clinicopathological data. Data were recorded separately for nuclear and cytoplasmic FGF2 expression. FGF2 expression was considered positive for cytoplasmic staining if unequivocally malignant cells expressed FGF2, and for nuclear staining with a Quick score >2 (31) . 
Statistical analysis and analysis of gene expression data
Results
Sensitivity to PD173074 in breast cancer cell lines
We examined the sensitivity of a panel of 31 breast cancer cell lines to the FGFR selective inhibitor PD173074 (24, 32) , treating cell lines plated in 96 well plates for 72 hours with 1μM PD173074. Eight breast cancer cell lines demonstrated a significant reduction in growth after 72 hours treatment (p<0.01 Student's T test). We noted that seven of these cell lines were of TN phenotype ( Figure 1A) , and that TN cell lines were more sensitive to PD173074 than other cell lines (P=0.011, Mann Whitney U Test) ( Figure 1A ). The sensitivity of the majority of cell lines to PD173074 was only modest ( Figure 1A ). We have previously demonstrated that one of the sensitive cell lines, CAL120, was substantially more sensitive to PD173074 growing in anchorage independent conditions (22) . Therefore, we assessed the sensitivity of the moderately sensitive cell lines in anchorage independent conditions. Substantially increased sensitivity to PD173074 under these conditions was demonstrated for TN cell lines MDAMB453, a HER2 amplified non-TN cell line that was sensitive to PD173074, has been shown to have an activating FGFR4 mutation (26) . The data shown above suggested a more pervasive sensitivity to PD173074 in TN breast cancer and we therefore examined the factors underlying the sensitivity of the remaining TN breast cancer cell lines.
Cellular consequences of FGFR inhibition
We examined downstream signalling in the TN breast cancer cell lines CAL51, Hs578T, and There was a substantial increase in subG1 cells in CAL120 and CAL51 in response to PD173074 suggesting the induction of apoptosis, but only a minor increase in Hs578T. To confirm that the increase in subG1 represented apoptosis, we measured PARP cleavage in response to PD173074, with evidence of increased PARP cleavage in CAL120 and Hs578T cell lines ( Figure 2C ). In addition, CAL120 and Hs578T demonstrated increased levels of activated Caspase 3/7 on exposure to PD173074 ( Figure 2D ). We could therefore confirm apoptosis in CAL120 and Hs578T, but not in CAL51.
Therefore, multiple basal-like TN breast cancer cell lines are sensitive to FGFR inhibitor PD173074 with a decrease in downstream signalling and this is associated with induction of both cell cycle arrest and apoptosis. 
Basal-like breast cancer cell lines express FGF2 ligand
We investigated the potential mechanisms underlying sensitivity to PD173074, in the cell lines where the mechanism of sensitivity was unknown (MDA-MB-157, CAL51, BT549, Hs578T). As well as being TN we noted that all these cell lines were basal-like in phenotype, and in particular the Basal B cell line subtype as described by Neve et al (25) . Basal B like cell lines are reported to be the cell line subtype most enriched in "stem cell-like" gene expression patterns, as well as having high levels of mesenchymal markers (25) . Assessing PD173074 sensitivity data according to cell line subtype, Basal B cell lines were more sensitive to PD173074 compared to cell lines of other subtypes (p=0.0328 Mann Whitney U test, Figure 1A ).
We first examined the presence of amplifications, by microarray-based comparative genomic hybridisation (aCGH), and demonstrated that none of these cell lines exhibited amplification of either the FGF receptors or FGF ligands (Supplementary Table 1 Figure 3D ), and had substantially elevated FGF2 protein in cellular lysates assessed by FGF2 ELISA (Supplementary Figure 3) .
Basal-like breast cancers express FGF2 ligand
To assess FGF2 expression in breast cancers, we examined the expression of FGF2 by immunohistochemistry (IHC) in a well characterised breast cancer tissue-microarray (27). Figure 4) , with stromal mRNA likely contaminating qPCR analysis in some tumours. Despite these limitations, both FGF2 cytoplasmic and FGF2 nuclear expression was associated with increased FGF2 mRNA expression ( Figure 4B ).
We showed above that basal-like breast cancer cell lines condition media with FGF2 ( Figure   3D ) implying secretion of FGF2. We therefore initially scored cytoplasmic FGF2 IHC expression, as this was likely to represent FGF2 stored in secretary granules. Cytoplasmic 
phenotype (triple negative: core basal-like 62% versus non-basal 0% p=0.0015 Fisher's exact test). FGF2 expression was associated with an adverse prognosis, due to the relatively early relapse of FGF2 expressing cancers ( Figure 4D ). However, it is unclear if this simply reflects an association with the basal-like subtype, a subtype that itself has a poor prognosis, or if FGF2 has a causal role in the poor prognosis.
To extend these observations, we interrogated the publicly available TransBIG data set (34) . Table 3 ), suggesting a distinct biological role for nuclear FGF2. Interestingly, the myoepithelial cells of normal breast ducts were observed to strongly express FGF2 in both nuclear and cytoplasmic compartments (Supplementary Figure 4) .
FGF2 promotes the growth of basal-like cell lines
To examine whether FGF2 potentially acted in an autocrine fashion, we silenced FGF2 expression using siRNA in CAL120, CAL51 and Hs578T cells which caused a significant reduction in cell line growth with both siFGF2 SMARTpool and individual siRNAs ( Figure 5A ).
In addition, we noted that silencing FRS2, the key adapter protein required for MAPK Figure 5D ). There was no effect of the neutralising antibody on control ER positive cell lines (MCF7, T47D, ZR75.1, data not shown).
FGFR inhibitors decrease growth of CAL51 xenografts in vivo
To investigate whether FGFR signalling presented a potential therapeutic target we established xenografts with the basal-like breast cancer cell line CAL51 cells in nude mice, and treated established tumours with PD173074 ( Figure 5E ). We were unable to establish xenografts reliably from Hs578T cells. PD173074 substantially reduced the growth of CAL51 xenografts compared to xenografts treated with vehicle alone ( Figure 5E ).
Discussion
Triple negative breast cancers have a poor prognosis and the factors that drive the proliferation of these breast cancers have been unclear. Here we provide evidence that It will be interesting in future research to identify the FGF receptor that mediates the FGF2 autocrine signalling. We show that FGFR1 likely mediates the autocrine signalling in the CAL120 cell line (Figure 5 ), although CAL120 is the only basal-like cell line that harbours high level FGFR1 amplification and the FGF2-FGFR1 autocrine loop could be specific to this cell line. We note that FGFR2 mRNA expression is higher in TN and basal-like breast cancers, compared to other breast cancers, in external data sets (Supplementary Figure 7) .
Recently, it has also been suggested that an FGF9-FGFR3 paracrine loop may promote breast cancer stem cell expansion, suggesting a potential role for FGFR3 (41). 
